Shares of Vital Therapies Inc (NASDAQ:VTL) have received a consensus rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold recommendation. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $6.00.
A number of equities research analysts have issued reports on VTL shares. Cantor Fitzgerald set a $18.00 price target on Vital Therapies and gave the stock a “buy” rating in a research note on Sunday, September 9th. BidaskClub lowered Vital Therapies from a “buy” rating to a “hold” rating in a research note on Thursday, September 6th. William Blair lowered Vital Therapies from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 12th. Raymond James lowered Vital Therapies from an “outperform” rating to a “market perform” rating and set a $6.00 price target for the company. in a research note on Wednesday, September 12th. Finally, ValuEngine lowered Vital Therapies from a “buy” rating to a “hold” rating in a research note on Wednesday, September 12th.
In other Vital Therapies news, Director Muneer A. Satter sold 11,382,277 shares of the stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $0.36, for a total transaction of $4,097,619.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Muneer A. Satter sold 447,500 shares of the stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $0.36, for a total transaction of $161,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 11,929,271 shares of company stock valued at $4,292,912 in the last three months. Insiders own 33.90% of the company’s stock.
Shares of VTL stock opened at $0.30 on Friday. Vital Therapies has a 52-week low of $0.23 and a 52-week high of $9.75. The firm has a market capitalization of $13.14 million, a price-to-earnings ratio of -0.23 and a beta of 4.26.
Vital Therapies (NASDAQ:VTL) last issued its quarterly earnings results on Tuesday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.03. As a group, equities analysts expect that Vital Therapies will post -1.11 earnings per share for the current fiscal year.
About Vital Therapies
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Featured Article: Moving Average – How it Helps Investors in Stock Selection
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.